||Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
||James A Fleming, Eric S Lightcap, Seth Sadis, Vala Thoroddsen, Christine E Bulawa, Ronald K Blackman
||Although the biochemical targets of most drugs are known, the biological consequences of their actions are typically less well understood. In this study, we have used two whole-genome technologies in Saccharomyces cerevisiae to determine the cellular impact of the proteasome inhibitor PS-341. By combining population genomics, the screening of a comprehensive panel of bar-coded mutant strains, and transcript profiling, we have identified the genes and pathways most affected by proteasome inhibition. Many of these function in regulated protein degradation or a subset of mitotic activities. In addition, we identified Rpn4p as the transcription factor most responsible for the cell's ability to compensate for proteasome inhibition. Used together, these complementary technologies provide a general and powerful means to elucidate the cellular ramifications of drug treatment.
||Proc. Natl. Acad. Sci. U.S.A. 2002; 99:1461-6
||Growth of pooled deletion collection was tested in the presence of proteasome inhibitors PS-341 (bortezomib) and PS-519.
These data may contain errors.
YeastPhenome.org is running in beta version.
The data are available for download, but, as of today, we cannot guarantee lack of errors or code bugs introduced during processing.
This warning will be removed after all cross-checks and validations have been completed.
In the meantime, please, be careful when using the data.